Skip to main content
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CTXR ISIN · US17322U2078 LEI · 5493005C10W36P4KQP40 US Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2018-05-23 Capital/Financing Update
Country US United States of America
Listing US CTXR

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com/

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Recent filings

Filing Released Lang Actions
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a Prospectus Supplement filed pursuant to Rule 424(b)(3) related to a Registration Statement. It updates and amends information about selling stockholders and their ownership percentages, including details about warrants and beneficial ownership. The document focuses on share ownership and selling stockholders rather than financial results, management changes, or other report types. This type of document is typically related to capital raising or share issuance activities, specifically updating information about shares available for sale by selling stockholders. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8222 characters) and content confirm it is a substantive filing, not just an announcement or certification.
2018-05-23 English
Regulatory Filings 2018
Regulatory Filings
2018-05-22 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2018
2018-05-11 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the sale of common stock shares by selling stockholders. It includes detailed information about the offering, company overview, risk factors, use of proceeds, financial statements, management discussion and analysis, and other disclosures typical of a securities offering document. It is not a financial report, earnings release, or management discussion report, but rather a registration/prospectus document for a securities offering. This type of document fits the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through a stock offering.
2018-04-27 English
Regulatory Filings 2018
Regulatory Filings
2018-04-27 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from Citius Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and discusses procedural acknowledgments related to the registration statement's effectiveness. There is no financial data, report content, or detailed disclosures typical of an Annual Report, Interim Report, or Earnings Release. The document is short (2342 characters) and serves as a formal regulatory communication about the registration statement's effective date, not the report itself. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2018-04-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.